⬅ Back to All Recalls

Octreotide for injectable suspension 10 mg/vial, Octreotide for injectable su...

# Major Recall Alert: Octreotide for Injectable Suspension Recalled Due to Quality Concerns in Good Manufacturing Practices (GMP)

Teva Canada Ltd. has issued a significant recall for their Octreotide injectable suspension products, including **10 mg/vial**, **20 mg/vial**, and **30 mg/vial** doses. This action is in response to quality concerns related to deficiencies in **Good Manufacturing Practices (GMP)**, which may compromise the safety and effectiveness of the affected products.

Here’s what you need to know about this recall and how you can take action to ensure your safety.

## Why This Recall is Important

When it comes to injectable medications, ensuring compliance with **Good Manufacturing Practices (GMP)** is critical to maintaining product quality, safety, and efficacy. GMP includes strict protocols designed to minimize risks in pharmaceutical manufacturing, including contamination or inconsistency in the product.

Teva Canada Ltd. identified deficiencies in these protocols that may have affected the quality of certain **Octreotide injectable suspension lots**. **Octreotide** is commonly used to treat conditions such as acromegaly, certain types of tumors, and other medical conditions that impact hormone levels. A compromised quality could pose serious risks to patient health, emphasizing the need for swift action.

## Details of the Recall

The recall encompasses three products manufactured by Teva Canada Ltd. under the **Octreotide** brand for injectable suspension:

- **10 mg/vial**
- **20 mg/vial**
- **30 mg/vial**

These products are being pulled due to concerns over adherence to **Good Manufacturing Practices (GMP)**. Quality deficiencies may compromise the safety, stability, or efficacy of the medicine, which can be life-threatening for users who rely on these treatments.

### Official Details:
- **Category**: Pharmaceutical (CAN)
- **Reason for Recall**: Quality concerns related to deficiencies in GMP.
- **Manufacturer**: Teva Canada Ltd.
- **Date Announced**: October 2023
- **Source**: [Government of Canada Official Recall Notice](https://recalls-rappels.canada.ca/en/alert-recall/octreotide-injectable-suspension-good-manufacturing-practices-concerns)

Consumers, healthcare professionals, and caregivers using or prescribing these products are urged to review the recall notice and take immediate precautions.

## What You Should Do

If you have possession of any **Octreotide injectable suspension** products from Teva Canada Ltd., here are steps you need to take:

- **Check Affected Lot Numbers**: Refer to the official recall notice or consult your prescribing professional to verify if your product is part of the recalled batch.
- **Contact Your Pharmacist or Healthcare Provider**: Discuss alternative medications or treatments if you are currently using this injectable suspension.
- **Report Adverse Reactions**: If you have experienced side effects or health complications related to this product, report directly to Health Canada or consult your doctor immediately.
- **Dispose of Recalled Products Properly**: Contact your pharmacist for advice on proper disposal. Do not throw recalled medications in the trash or flush them.

## Stay Safe – Get Instant Recall Alerts

Safety concerns about essential medications, such as Octreotide injectable suspension, highlight the importance of staying informed. Protect yourself and your loved ones by signing up for instant recall notifications.

**Stay updated in real-time about pharmaceutical recalls** and ensure your safety with our free recall alert app.
[**Download the app today**](#) to receive notifications for product recalls, including medications, food, and more, directly to your smartphone.

---

Taking quick action can prevent health risks associated with defective or unsafe medications. Stay vigilant and informed to prioritize your health. For more information, please visit the official recall notice from the Government of Canada [**here**](https://recalls-rappels.canada.ca/en/alert-recall/octreotide-injectable-suspension-good-manufacturing-practices-concerns).

Don’t forget to stay proactive—download our app now and safeguard yourself from future recalls!

⬅ Back to All Recalls